The China Securities Regulatory Commission has approved the IPO registration of Yulong Technology on the ChiNext board.
On August 28, the China Securities Regulatory Commission issued the "Approval for Chongqing Yulong Optoelectronic Technology Co., Ltd.'s Initial Public Offering Registration."
On August 28, the China Securities Regulatory Commission (CSRC) issued a reply granting approval for Chongqing Yulong Optoelectronics Technology Co., Ltd. to register its initial public offering (IPO) of stocks. It is reported that Yulong Technology plans to list on the Shenzhen Stock Exchange's Growth Enterprise Market, with CITIC Securities as its sponsor, aiming to raise 1 billion yuan.
The prospectus shows that Yulong Technology focuses on the research, development, production, and sales of intelligent control cards and precision functional devices related to new semiconductor display panels, and is committed to becoming the most valuable company in China's intelligent control field. The company's main products are widely used by leading domestic semiconductor display panel manufacturers. According to Frost & Sullivan data, in 2024, the company is expected to hold approximately 14% market share in Chinas intelligent control card applications (including laptops, tablets, monitors, televisions, and automotive screens), ranking first in the market and establishing a leading position in the industry.
Related Articles

BIREN TECH (06082) announced its interim results, with revenue of 1.236 billion yuan, a year-on-year increase of 1997.6%.

SHANDONG XINHUA (00719) has obtained the drug registration certificate for Dapoxetine Hydrochloride Tablets.

YUEXIU PROPERTY (00123) released its interim results, with revenue of 36.65 billion yuan and contract sales of 50.51 billion yuan, ranking eighth in the country. All three red lines are green.
BIREN TECH (06082) announced its interim results, with revenue of 1.236 billion yuan, a year-on-year increase of 1997.6%.

SHANDONG XINHUA (00719) has obtained the drug registration certificate for Dapoxetine Hydrochloride Tablets.

YUEXIU PROPERTY (00123) released its interim results, with revenue of 36.65 billion yuan and contract sales of 50.51 billion yuan, ranking eighth in the country. All three red lines are green.

RECOMMEND





